Report an error

Spotted something inaccurate in “NEJM Correspondence Raises Concerns Over Sacituzumab Govitecan Trial in Triple-Negative Breast Cancer”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.